Biomatters

Investors

Biotechnology - A ‘sunrise’ industry

Biotechnology is a growth industry, both in the traditional academic and commercial sense. Biotech as an industry is a vital economic development focus for many governments around the world, and New Zealand is no exception. Bioinformatics, quite simply, is the use of technology to analyze biological information.

According to the market research report on the bioinformatics industry, “Bioinformatics Market Update (2006) by RNCOS, the bioinformatics industry worldwide reached $1,435million in 2005 with a growth of 17 % from 2004. Analysts project an annual market growth rate of 15.8% to US$3 billion by 2010. The largest markets for Bioinformatics include the USA, Europe and Japan. The total European bioinformatics market is set to expand from nearly $310million in 2004 to $720million by 2011" (source: world Bioinformatics market 2005 – 2010) RNOS Strategic Report, Nov 2005).

Biotechnology in New Zealand

New Zealand has a strong background in scientific innovation and discovery. The current biotech industry offers world-class research to occur in a stable, cost-competitive and strategic part of the world. New Zealand has an enviable tradition of producing world-class scientists and health researchers, renown for scientific innovation and discovery on a global scale and collaborating internationally with many of the world’s top institutes and companies.

Biotechnology and Information Technology were identified as two of the three top industries that New Zealand chose to focus funding, support and government initiative in 2001 going forward. Why? Because of New Zealand’s commitment to advancing its economy and resources towards the most in-demand, profitable and best positioned industries on the world stage, Investing in New Zealand

In New Zealand, research and development is 100% tax deductible with a political culture that encourages investment in innovative companies and technology. The New Zealand government puts 25% of its total research investment in biotechnology- much higher than any other member of the OECD.

To encourage private sector investments in the industry, the government also provides an R&D tax credit of 15% which is amongst the most generous in the OECD . The New Zealand dollar is well placed for overseas investors to get real value from investment. Additionally, there is no capital gains tax in New Zealand for offshore investors, making it easier for investors to participate in the ongoing commercialization of New Zealand’s technology companies.

“Within New Zealand, just over 50% of the venture dollar invested in 2007 were directed to the biotech industry giving biotech companies a much larger slice of the venture pie than is typical in the US or Europe”
(Source: Ernst & Young Global biotechnology Report 2008 – Beyond Borders)

Biomatters has been the recipient of nearly NZ$900,000 of non-dilutive, matched funding through government grants. This means that when Biomatters receives investment from shareholders, much of the investment is eligible for a dollar-for-dollar match through the New Zeland Trade and Enterprise grant funds.

What Biomatters Has to Offer

Biomatters is rapidly increasing its user base and revenue stream within the global market. Few companies can boast several national and international awards, quarterly compounding revenue growth since inception, high-profile projects with international technology and research partners and government matched-funding programs.

Biomatters seeks investors interested in securing a shareholding of a technically gifted, highly relevant company in the rapidly expanding bioinformatics technology space. We welcome the opportunity to discuss the exciting benefits of investing in Biomatters with existing and future shareholders.

As a Shareholder

Biomatters maintains open and honest relationships with our shareholders, prospective investors and the wider investment community. We manage these relationships efficiently, transparently and consistently in accordance with company policies and relevant securities rules and laws.

We communicate regularly with our shareholders in various ways including:

  • Our annual general meeting
  • Quarterly report updates
  • Investor meetings
  • One-on-one meetings with the CEO and Board Members
  • Road shows and international conferences

For existing shareholders, please contact us to receive an archived copy of our AGM presentation and minutes, annual or quarterly report.

If you would like to request investor information, please contact us on invesjtmentk@biom2atterjs.coms